CERS vs HAE

For growth investors, Cerus Corporation (CERS) is the stronger pick with 14.

3% revenue growth year-over-year, versus -2. 0% for Haemonetics Corporation (HAE). Haemonetics Corporation (HAE) offers the better valuation at 26. 5x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Cerus Corporation (CERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Haemonetics Corporation (HAE) delivered a total return of -10.

9%, compared to -57. 5% for Cerus Corporation (CERS). Over 10 years, the gap is even starker: HAE returned +99. 2% versus CERS's -54. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haemonetics Corporation (HAE) is the lower-risk stock at 0.

48β versus Cerus Corporation's 2. 13β — meaning CERS is approximately 347% more volatile than HAE relative to the S&P 500. On balance sheet safety, Haemonetics Corporation (HAE) carries a lower debt/equity ratio of 137% versus 149% for Cerus Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cerus Corporation (CERS) is pulling ahead at 14.

3% versus -2. 0% for Haemonetics Corporation (HAE). On earnings-per-share growth, the picture is similar: Cerus Corporation grew EPS 25. 5% year-over-year, compared to -38. 1% for Haemonetics Corporation. Over a 3-year CAGR, CERS leads at 8. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haemonetics Corporation (HAE) is the more profitable company, earning 7.

3% net margin versus -7. 6% for Cerus Corporation — meaning it keeps 7. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HAE leads at 11. 7% versus -17. 6% for CERS. At the gross margin level — before operating expenses — HAE leads at 59. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for HAE: 55.

6% to $84. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Haemonetics Corporation (HAE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

48)). Cerus Corporation (CERS) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HAE: +99. 2%, CERS: -54. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.